Drugs / Coronavirus-specific T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05141058 | Oct 2021 → Nov 2028 expected | COVID-19 | Children's National Research Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coronavirus-specific T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05141058 ↗ |
| Known as | CST | “Coronavirus-specific T cell (CST)” NCT05141058 ↗ |
| Modality | Cell therapy | “coronavirus-specific T cell (CST) therapy” NCT05141058 ↗ |
| Route | Other | “after CST infusion” NCT05141058 ↗ |